MD3645553T2 - Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane - Google Patents

Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane

Info

Publication number
MD3645553T2
MD3645553T2 MDE20200493T MDE20200493T MD3645553T2 MD 3645553 T2 MD3645553 T2 MD 3645553T2 MD E20200493 T MDE20200493 T MD E20200493T MD E20200493 T MDE20200493 T MD E20200493T MD 3645553 T2 MD3645553 T2 MD 3645553T2
Authority
MD
Moldova
Prior art keywords
recombinant viral
tropism
human cells
genetic material
viral particles
Prior art date
Application number
MDE20200493T
Other languages
English (en)
Inventor
Leah Sabin
Christopher Schoenherr
Aris N Economides
Christos Kyratsous
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3645553(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MD3645553T2 publication Critical patent/MD3645553T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Prezenta invenţie se referă la compoziţii şi metode pentru redirecţionarea particulelor de capside virale recombinate printr-o pereche specifică de legare proteină: proteină, care formează o legătură covalentă, de exemplu, izopeptidă, pentru a afişa un ligand de ţintire pe proteină capsidei, totodată ligandul de ţintire se leagă în mod specific cu un marker de suprafaţă celulară exprimat pe celula de interes.
MDE20200493T 2017-06-27 2018-06-27 Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane MD3645553T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762525708P 2017-06-27 2017-06-27
PCT/US2018/039878 WO2019006046A2 (en) 2017-06-27 2018-06-27 RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND USES THEREOF FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS

Publications (1)

Publication Number Publication Date
MD3645553T2 true MD3645553T2 (ro) 2023-07-31

Family

ID=63080488

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20200493T MD3645553T2 (ro) 2017-06-27 2018-06-27 Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane

Country Status (28)

Country Link
US (1) US20200140492A1 (ro)
EP (2) EP3645553B1 (ro)
JP (3) JP2020525020A (ro)
KR (1) KR20200021987A (ro)
CN (2) CN110997699A (ro)
AU (2) AU2018290885B2 (ro)
BR (1) BR112019027866A2 (ro)
CA (1) CA3066950A1 (ro)
CL (2) CL2019003843A1 (ro)
CO (1) CO2019014684A2 (ro)
CY (1) CY1126149T1 (ro)
DK (1) DK3645553T5 (ro)
ES (1) ES2943020T3 (ro)
FI (1) FI3645553T3 (ro)
HR (1) HRP20230538T1 (ro)
HU (1) HUE061908T2 (ro)
IL (1) IL271570A (ro)
LT (1) LT3645553T (ro)
MA (1) MA49514B1 (ro)
MD (1) MD3645553T2 (ro)
MX (2) MX2020000246A (ro)
PH (1) PH12019550269A1 (ro)
PL (1) PL3645553T3 (ro)
PT (1) PT3645553T (ro)
RS (1) RS64233B1 (ro)
SG (1) SG11201911614XA (ro)
SI (1) SI3645553T1 (ro)
WO (1) WO2019006046A2 (ro)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
JP2021516048A (ja) * 2018-02-28 2021-07-01 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 遺伝子及びタンパク質の送達のためのａａｖに基づくモジュールシステム
US11453883B2 (en) 2018-04-05 2022-09-27 Bio-Rad Abd Serotec Gmbh Display systems for proteins of interest
JP2022525775A (ja) * 2019-03-18 2022-05-19 バイオ－ラッド エービーディー セロテック ゲーエムベーハー ＳｐｙＴａｇ含有ペリプラズム融合タンパク質のプロテアーゼＴＳＰ及びＯＭＰＴ分解からの保護
BR112021023692A2 (pt) * 2019-05-24 2022-01-04 Regeneron Pharma Partícula viral de vírus adeno-associado recombinante, proteína de capsídeo de vírus adeno-associado, molécula de ácido nucleico, célula empacotadora, métodos de produção de uma partícula viral e de distribuição de um nucleotídeo, e, composição farmacêutica
EP3983117A4 (en) * 2019-06-11 2023-06-21 Chevron U.S.A. Inc. NATURAL GAS CONTAMINANT REMOVAL MEMBRANES AND METHODS OF USE THEREOF
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
US20230002451A1 (en) * 2019-11-08 2023-01-05 President And Fellows Of Harvard College Viral capsid polypeptides
CN114632148B (zh) * 2020-12-15 2024-08-09 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
EP4426359A1 (en) 2021-11-04 2024-09-11 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to skeletal muscle
CN114213505B (zh) * 2021-12-10 2022-09-20 和元生物技术（上海）股份有限公司 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240168018A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and evaluating viruses and virus-like particles
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286981C (zh) * 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
DK2158211T3 (en) 2007-05-31 2016-12-05 Medigene Ag Mutated structural protein of a parvovirus
ES2595376T3 (es) 2009-12-10 2016-12-29 Regeneron Pharmaceuticals, Inc. Ratones que producen anticuerpos de cadena pesada
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
US20160018835A1 (en) * 2014-07-18 2016-01-21 Retroficiency, Inc. System and method for virtual energy assessment of facilities
US10526376B2 (en) * 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
US20180298098A1 (en) 2015-02-26 2018-10-18 Var2 Pharmaceutical Aps Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
EP3141600A1 (en) 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
CN109996880A (zh) 2016-08-18 2019-07-09 加利福尼亚大学董事会 基于模块化aav递送系统的crispr-cas基因组工程
JP2021516048A (ja) * 2018-02-28 2021-07-01 ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 遺伝子及びタンパク質の送達のためのａａｖに基づくモジュールシステム

Also Published As

Publication number Publication date
RU2020101596A (ru) 2021-07-27
FI3645553T3 (fi) 2023-05-22
MA49514B1 (fr) 2023-06-28
WO2019006046A2 (en) 2019-01-03
HUE061908T2 (hu) 2023-09-28
MX2020000246A (es) 2020-08-10
AU2018290885B2 (en) 2023-07-27
IL271570A (en) 2020-02-27
PH12019550269A1 (en) 2021-01-11
CN116891534A (zh) 2023-10-17
ES2943020T3 (es) 2023-06-08
CO2019014684A2 (es) 2020-01-17
PT3645553T (pt) 2023-05-08
CY1126149T1 (el) 2023-11-15
SG11201911614XA (en) 2020-01-30
DK3645553T3 (da) 2023-05-22
WO2019006046A3 (en) 2019-02-14
PL3645553T3 (pl) 2023-07-17
AU2018290885A1 (en) 2020-01-16
MX2023009051A (es) 2023-08-10
CA3066950A1 (en) 2019-01-03
AU2023204611A1 (en) 2023-08-03
CL2019003843A1 (es) 2020-07-24
JP2024071769A (ja) 2024-05-24
CL2020003438A1 (es) 2021-07-23
JP2022186991A (ja) 2022-12-15
RS64233B1 (sr) 2023-06-30
DK3645553T5 (da) 2024-08-26
EP3645553B1 (en) 2023-03-15
MA49514A (fr) 2020-05-06
SI3645553T1 (sl) 2023-06-30
CN110997699A (zh) 2020-04-10
RU2020101596A3 (ro) 2022-03-22
US20200140492A1 (en) 2020-05-07
EP4219529A1 (en) 2023-08-02
HRP20230538T1 (hr) 2023-08-04
LT3645553T (lt) 2023-04-25
KR20200021987A (ko) 2020-03-02
EP3645553A2 (en) 2020-05-06
JP2020525020A (ja) 2020-08-27
BR112019027866A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
MD3645553T2 (ro) Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CY1121934T1 (el) Αντισωματα anti-fcrn
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MD3645551T2 (ro) Vectori virali recombinanţi modificați cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane
MX2024004646A (es) Proteinas de union de cadena unica de fragmento variable cd3.
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
NZ736026A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2019007921A (es) Nuevos agentes de union a ha.
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX350773B (es) Métodos y composiciones para el control de malezas.
MX348495B (es) Metodos y composiciones para el control de malezas.
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
MX365382B (es) Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2014055836A3 (en) Serine protease molecules and therapies
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MX2018009389A (es) Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MA39096B1 (fr) Anticorps spécifiques à fcrn